News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News AHA 2017 Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins Caitlin E. Cox November 14, 2017
News Conference News AHA 2017 CANTOS: Big Drop in CVD Events Among Canakinumab Responders Michael O'Riordan November 13, 2017
News Conference News TCT 2017 TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More Shelley Wood October 20, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Conference News ESC 2017 Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels Michael O'Riordan August 29, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Conference News SCCT 2017 Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking Yael L. Maxwell July 13, 2017
News Conference News ACC 2017 People Living in Amazon Rainforest Provide Clues to Coronary Protection L.A. McKeown March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions Shelley Wood March 09, 2017
News Conference News ISET 2017 Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not? Caitlin E. Cox February 06, 2017